General Hospital Of Thessloniki G Gennimatas

The site is conducting trials targeting severe bacterial infections such as hospital‑acquired pneumonia caused by Acinetobacter and fungal bloodstream infections. One study evaluates a monoclonal antibody that neutralizes interferon‑gamma in sepsis driven by a specific endotype, while another assesses adjunctive rIFN‑γ therapy for candidemia. The purpose is to test new therapies that improve survival and pathogen clearance.

• Sepsis endotype‑targeted therapy
• Candidemia adjunctive treatment
• Hospital‑acquired bacterial pneumonia

General Hospital Of Thessloniki G Gennimatas hosts 10 trials with 5 investigators in this area.

Trials focus on reducing major cardiac events in patients with hypertension, elevated lipoprotein(a), and established atherosclerotic disease. One study examines muvalaplin for preventing MACE‑4, while another combines a novel agent with empagliflozin to lower time to cardiovascular death, heart‑failure hospitalization, or urgent visit. The goal is to evaluate the effectiveness of new drugs in preventing heart complications.

• Muvalaplin cardiovascular outcomes
• Vicadrostat‑empagliflozin combination
• Lipoprotein(a) risk reduction

The internal medicine clinic leverages its cardiovascular expertise to advance heart‑health research.

The department runs oncology trials for non‑muscle invasive bladder cancer that is unresponsive to standard intravesical therapy. The study compares a novel agent alone or with an immune checkpoint inhibitor, aiming to improve complete response rates and disease‑free survival. The purpose is to test innovative treatments for bladder tumor control.

• TAR‑200 monotherapy
• TAR‑200 plus cetrelimab
• Bladder cancer response assessment

These investigations support patients who are not candidates for radical cystectomy.

Multiple studies address obesity, overweight, and metabolic dysfunction. A trial of retatrutide investigates its impact on cardiovascular and kidney outcomes in obese adults, while another compares a dual‑agonist therapy with tirzepatide for glycemic control and weight loss in type 2 diabetes. Additional research evaluates a GLP‑1/GCGR agonist versus semaglutide and placebo for kidney‑disease progression. The goal is to identify therapies that simultaneously improve metabolic parameters and organ health.

• Retatrutide cardiovascular and renal outcomes
• CagriSema vs tirzepatide
• CagriSema kidney disease study

The site’s metabolic program integrates obesity management with diabetes care.

The hospital investigates treatments for severe bacterial pneumonia requiring ventilation. A single‑day dose‑escalation study evaluates OMN6 versus placebo in patients with hospital‑acquired or ventilator‑associated pneumonia caused by Acinetobacter. The aim is to assess safety, tolerability, and early efficacy of a novel antimicrobial peptide.

• OMN6 safety in HABP/VABP
• Acinetobacter‑related pneumonia
• Single‑dose escalation design

Findings may expand therapeutic options for critical‑care respiratory infections.

While no virus‑specific trials are listed, the site maintains capacity to study viral infections as part of its broad internal medicine portfolio, ready to enroll participants for future antiviral research.

• Preparedness for viral infection studies
• Potential COVID‑19 or influenza trials
• Collaborative virology network

The department’s flexible infrastructure supports rapid initiation of virus‑related protocols.

Some investigations at the clinic span multiple systems or address overall patient health, such as combined metabolic‑cardiovascular studies and safety assessments across diverse populations.

• Integrated metabolic‑cardiovascular trials
• Broad safety‑tolerability studies
• Cross‑disciplinary research initiatives

These projects reflect the holistic approach of General Hospital Of Thessloniki G Gennimatas.